ISDA

Deposition Date 2021-05-21

Release Date 2021-07-14

Last Version Date 2024-10-16

Entry Detail

PDB ID:

7MYR

Keywords:

HYDROLASE

Title:

BACE-1 in complex with compound #18

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.72 Å

R-Value Free:

0.19

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Beta-secretase 1
Gene (Uniprot):BACE1
Chain IDs:A, B
Chain Length:442
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P56817 Pfam ID:PF00026 EC:3.4.23.46

Ligand Molecules

GOL

SO4

ZRD

Primary Citation

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.

McKinzie, D.L, Winneroski, L.L, Green, S.J, Hembre, E.J, Erickson, J.A, Willis, B.A, Monk, S.A, Aluise, C.D, Baker, T.K, Lopez, J.E, Hendle, J, Beck, J.P, Brier, R.A, Boggs, L.N, Borders, A.R, Cocke, P.J, Garcia-Losada, P, Lowe, S.L, Mathes, B.M, May, P.C, Porter, W.J, Stout, S.L, Timm, D.E, Watson, B.M, Yang, Z, Mergott, D.J.Show

J.Med.Chem. 64 8076 8100 (2021)

PMID: 34081466 DOI: 10.1021/acs.jmedchem.1c00489

Abstact

The beta-site APP cleaving enzyme 1, known as BACE1, has been a widely pursued Alzheimer's disease drug target owing to its critical role in the production of amyloid-beta. We have previously reported the clinical development of LY2811376 and LY2886721. LY2811376 advanced to Phase I before development was terminated due to nonclinical retinal toxicity. LY2886721 advanced to Phase II, but development was halted due to abnormally elevated liver enzymes. Herein, we report the discovery and clinical development of LY3202626, a highly potent, CNS-penetrant, and low-dose BACE inhibitor, which successfully addressed these key development challenges.

Legend

Protein

Chemical

Disease

Primary Citation of related structures